LEO Pharma reports positive data from Phase III plaque psoriasis trial

Leo Pharma has announced positive data from the Phase III clinical trial of Enstilar (LEO 90100) in Chinese adult patients with stable plaque psoriasis.

An aerosol spray foam, enstilar combines 50mcg/g calcipotriol monohydrate and 0.5mg/g betamethasone dipropionate.